Related Experiment Video
Updated: Sep 4, 2025

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
Published on: July 26, 2018
Cardiac amyloidosis: a review of the literature
Nils de Marneffe1, R Dulgheru2, A Ancion2
1Department of Cardiology, University Hospital of Liege, Liege, Belgium.
Insights
Cardiac amyloidosis, a rare condition, presents with heart failure and requires timely diagnosis through imaging and lab tests. Management focuses on treating symptoms and preventing further amyloid buildup.
Area of Science:
- Cardiology
- Internal Medicine
- Rare Diseases
Background:
- Cardiac amyloidosis is a rare disease with significant morbidity and mortality.
- It commonly presents as heart failure with preserved ejection fraction, restrictive cardiomyopathy, or hypertrophic obstructive cardiomyopathy.
- Key types include light chain (AL), transthyretin (ATTR), and secondary (AA) amyloidosis.
Purpose of the Study:
- To provide a comprehensive review of the management strategies for cardiac amyloidosis.
Main Methods:
- Diagnosis relies on imaging (echocardiography, bone scintigraphy, cardiac MRI) and laboratory tests (blood, urine).
- Tissue biopsy may be required for definitive diagnosis.
- Treatment involves managing symptoms, complications, and preventing further amyloid deposition.
Main Results:
- Cardiac amyloidosis can manifest with varied left ventricular characteristics, including preserved ejection fraction and hypertrophy.
- Multimodality imaging and biochemical analyses are crucial for diagnosis.
- Therapeutic approaches address both the disease burden and its sequelae.
Conclusions:
- Effective management of cardiac amyloidosis requires a multi-faceted approach.
- Early diagnosis and tailored treatment are essential for improving patient outcomes.
- Ongoing research continues to refine treatment protocols for this complex condition.
Abstract:
Cardiac amyloidosis is a rare disease associated with severe morbidity and mortality. There are three main types of amyloidosis associated with cardiac involvement: light chain (AL), familial or senile (ATTR) and secondary amyloidosis (AA). Cardiac amyloidosis often results in heart failure with preserved left ventricular ejection fraction, may display echocardiographic features of restrictive cardiomyopathy associated with left ventricular hypertrophy or mimic hypertrophic obstructive cardiomyopathy. However, left ventricular systolic dysfunction and normal wall thickness can sometimes be encountered. Imaging studies (echocardiography, bone scintigraphy, cardiac magnetic resonance) and blood and urine analysis are usually the main tools for the diagnosis. Sometimes, a tissue biopsy may be necessary. Treatment, which is constantly improving, will be carried out on two fronts: treatment of the symptoms and complications that the disease already caused and prevention of additional amyloid deposits while managing the concomitant complications. The purpose of this article is to review the management of cardiac amyloidosis.
More Related Videos
Related Concept Videos
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Cardiomyopathy II: Dilated Cardiomyopathy

